Treatment Options for Hypertension

Patients with chronic hypertension face a dramatically higher risk of heart attack, stroke, heart failure, kidney disease and death. Because of these risks, the disease is treated aggressively with lifestyle changes and prescription medication. Unfortunately, in half of treated patients these steps alone are not enough to control blood pressure. Additionally, some patients have a hard time tolerating the side-effects of medication. Clearly, another treatment option is needed. Renal Denervation (RDN) treatment was developed to give doctors a minimally invasive endovascular treatment to accomplish this goal.

Treating mild hypertension

Patients with mild hypertension are advised to make behavioral and dietary changes such as losing weight, exercising, reducing sodium intake and increasing potassium intake. If these approaches are unsuccessful, drug treatment is usually prescribed.

Pharmaceutical Therapy

While pharmaceutical therapy plays a role in hypertension management, these are not always effective. Approximately 50 percent of patients with hypertension remain uncontrolled, and approximately 15-20 percent of those are resistant.2

Renal Denervation Treatment

Renal Denervation (RDN) addresses uncontrolled hypertension by reducing the drive of the sympathetic nervous system, which is central to blood pressure regulation. It is a minimally invasive procedure that modulates the output of the renal nerves located outside the renal artery walls and represents a breakthrough approach and first-of-its-kind device-based treatment for resistant hypertension.

Selectively quieting hyperactive renal nerves causes a reduction in the kidneys’ production of hormones that raise blood pressure.` Renal Denervation (RDN) treatment was developed to give doctors a minimally invasive endovascular treatment to accomplish this goal.

Medtronic’s Symplicity™3 renal denervation system is designed to allow doctors to deliver energy to the nerves surrounding the renal arteries.

References

  1. Lloyd-Jones D et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010;121(7):e46-e215
  2. Symplicity is a trademark of Medtronic, Inc. and is registered in one or more countries of the world.

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.

Last updated: 22 Mar 2012

Section Navigation

Additional information

Take Charge

    • Medtronic RDN Screenshot
Europe